SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.

NCT Number	NCT07129187
Lead Sponsor	Chuan Wang
Conditions	Early Breast Cancer, HER2 + Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Enrollment	30 participants
Start Date	2025-10
Primary Completion	2026-10 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2025-08-26